IIM
BBIO icon

Ironwood Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Ironwood Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.56M Buy
61,163
+203
+0.3% +$14.2K 1.58% 12
2026
Q1 		$4.53M Sell
60,960
-834
-1% -$60.5K 1.89% 8
2025
Q4 		$4.73M Sell
61,794
-129
-0.2% -$8.47K 1.99% 8
2025
Q3 		$3.22M Sell
61,923
-523
-0.8% -$25.5K 1.4% 16
2025
Q2 		$2.7M Sell
62,446
-2,056
-3% -$74.8K 1.31% 16
2025
Q1 		$2.23M Buy
64,502
+1,345
+2% +$45.4K 1.22% 22
2024
Q4 		$1.73M Buy
63,157
+338
+0.5% +$8.73K 0.86% 30
2024
Q3 		$1.6M Sell
62,819
-185
-0.3% -$4.86K 0.78% 38
2024
Q2 		$1.6M Sell
63,004
-47
-0.1% -$1.28K 0.85% 34
2024
Q1 		$1.95M Sell
63,051
-1,453
-2% -$49.4K 0.95% 31
2023
Q4 		$2.6M Sell
64,504
-33
-0.1% -$991 1.37% 18
2023
Q3 		$1.7M Sell
64,537
-1,826
-3% -$51.8K 1.04% 28
2023
Q2 		$1.14M Sell
66,363
-2,500
-4% -$37.6K 0.66% 47
2023
Q1 		$1.14M Buy
68,863
+620
+0.9% +$7.23K 0.71% 47
2022
Q4 		$520K Sell
68,243
-3,723
-5% -$35.6K 0.34% 91
2022
Q3 		$715K Buy
71,966
+82
+0.1% +$852 0.5% 72
2022
Q2 		$653K Buy
71,884
+55
+0.1% +$460 0.44% 83
2022
Q1 		$729K Buy
71,829
+1,770
+3% +$18.2K 0.4% 89
2021
Q4 		$1.17M Buy
70,059
+44,740
+177% +$1.89M 0.58% 56
2021
Q3 		$1.19M Sell
25,319
-26
-0.1% -$1.39K 0.62% 52
2021
Q2 		$1.54M Sell
25,345
-494
-2% -$28.2K 0.78% 37
2021
Q1 		$1.59M Buy
25,839
+158
+0.6% +$10.3K 0.84% 29
2020
Q4 		$1.83M Sell
25,681
-607
-2% -$29.3K 1.07% 23
2020
Q3 		$986K Sell
26,288
-46
-0.2% -$1.45K 0.7% 41
2020
Q2 		$859K Buy
26,334
+3,924
+18% +$120K 0.67% 52
2020
Q1 		$650K Buy
+22,410
New +$695K 0.65% 54

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ironwood Investment Management's BBIO Position: Q2 2026 in Review

Ironwood Investment Management increased its BridgeBio Pharma (BBIO) stake by 0.33% in Q2 2026, buying an estimated $14.2K and bringing the position to 61,163 shares worth $4.56M. The position accounts for 1.58% of the portfolio, ranked #12.

Ironwood Investment Management first reported a position in BBIO in Q1 2020 and has held it in 26 quarters since. The position peaked at $4.73M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Ironwood Investment Management held 61,163 shares of BridgeBio Pharma worth $4.56M as of Q2 2026.
  • Ironwood Investment Management bought 203 BridgeBio Pharma shares in Q2 2026, an estimated $14.2K.
  • BridgeBio Pharma made up 1.58% of Ironwood Investment Management's portfolio in Q2 2026, its #12 holding.
  • Ironwood Investment Management first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 26 quarters since.
  • Ironwood Investment Management's BridgeBio Pharma position peaked at $4.73M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ironwood Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.